Sep 4, 2023
by Suyeon Jang
We’re proud to share an exciting milestone from one of our portfolio companies, Ingenium Therapeutics.
Ingenium, which we invested in back in April 2022, has officially received approval to begin Phase 2 clinical trials in Korea. The trial will take place across four hospitals, marking a significant step forward in the company’s mission to advance next-generation NK cell therapies.
We had the pleasure of visiting Ingenium’s office on the day the trial approval was publicly announced in June 2023—a moment filled with optimism and anticipation. Here’s a photo we captured during that visit, celebrating this important achievement together.
Ingenium Therapeutics Receives Phase 2 Approval for AML Therapy, ‘ZenGlucel’
Ingenium Therapeutics has received approval from the Korean Ministry of Food and Drug Safety (MFDS) to begin Phase 2 clinical trials for ZenGlucel, its memory NK cell therapy targeting acute myeloid leukemia (AML).
The trial will be conducted across four leading hospitals in Korea: Asan Medical Center, Seoul St. Mary’s Hospital, Samsung Medical Center, and Ewha Womans University Mokdong Hospital. The primary goal is to evaluate whether administering NK cells following standard AML treatment can improve overall patient survival.
NK (natural killer) cells are a promising new approach in cancer treatment due to their ability to directly kill tumor cells. In earlier studies, ZenGlucel demonstrated both safety and efficacy in leukemia patients—with survival rates more than three times higher compared to patients who had only received stem cell transplants.
Ingenium’s NK cells are derived from healthy donor peripheral blood using a distinct process that sets them apart from conventional NK cell production methods.
Looking ahead, the company is also developing memory NK therapies targeting solid tumors such as lung, liver, and colorectal cancers, as well as working on next-generation CAR-NK and NK engager platforms.
Source: HIT News – [Read full article]
Back to News